This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Theravance (TBPH) Drops on Q3 Earnings Miss, Revenues In Line
by Zacks Equity Research
Theravance (TBPH) falls more than 13% as it reports wider-than-expected loss for the third quarter of 2020. Revenues meet estimates.
Mylan's (MYL) Q3 Earnings Surpass Estimates, Sales Miss
by Zacks Equity Research
Mylan (MYL) beats on Q3 earnings but misses on sales. The company is all set to merge with Pfizer's Upjohn business later in the month.
Seagens (SGEN) Q3 Earnings Rise Y/Y, Adcetris Sales View Cut
by Zacks Equity Research
Seagen's (SGEN) bottom line grows year over year in Q3 while revenues beat estimates. The company lowers the sales guidance for its lead product Adcetris.
Sanofi's (SNY) Q3 Earnings & Sales Miss, 2020 View Raised
by Zacks Equity Research
Sanofi's (SNY) earnings and sales miss estimates. It raises its earnings growth expectations for the year.
Glaxo (GSK) Q3 Earnings Top, Vaccines Segment on Recovery Path
by Zacks Equity Research
Glaxo (GSK) witnesses recovery in vaccinations rates in the third quarter. Performance of Pharmaceuticals and Consumer Healthcare businesses improve.
Gilead (GILD) Beats on Q3 Earnings & Sales, Lowers '20 View
by Zacks Equity Research
Gilead (GILD) reports better-than-expected results for the third quarter owing to Veklury sales. However, the company lowers annual guidance.
Company News for Oct 29, 2020
by Zacks Equity Research
Companies In The News Are: GE, MA, SNE, GSK.
Glaxo (GSK) Beats Earnings Estimates in Q3, Revenues Miss
by Zacks Equity Research
Glaxo beats earnings estimates in the third quarter of 2020 but misses the same for revenues. Stock down.
Drug/Biotech Stock Q3 Earnings on Oct 28: GSK, AMGN & More
by Zacks Equity Research
Let us take a look at four drug/biotech companies due to release their quarterly results on Oct 28.
Why GlaxoSmithKline (GSK) Might Surprise This Earnings Season
by Zacks Equity Research
GlaxoSmithKline (GSK) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Will AbbVie (ABBV) Q3 Earnings Recover From Coronavirus Woes?
by Zacks Equity Research
Investors will focus on any recovery in AbbVie's (ABBV) sales amid the coronavirus pandemic when it reports third-quarter results.
Roche (RHHBY) Inks Deal to Develop Oral Coronavirus Treatment
by Zacks Equity Research
Roche (RHHBY) signs a contract with privately-held Atea Pharmaceuticals for jointly developing AT-527, an oral treatment for COVID-19 patients.
Is a Beat in Store for Glaxo (GSK) This Earnings Season?
by Zacks Equity Research
Glaxo's (GSK) Pharmaceutical and Consumer Healthcare segments are likely to have driven third-quarter sales. Results will provide clarity on the impact of coronavirus on the company's vaccine business.
GlaxoSmithKline (GSK) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
GlaxoSmithKline (GSK) closed at $35.35 in the latest trading session, marking a -1.91% move from the prior day.
Merck (MRK) to Report Q3 Earnings: Is a Beat in the Cards?
by Zacks Equity Research
Investor focus is likely to be on the sales numbers of Merck's (MRK) blockbuster oncology medicine, Keytruda.
Merck (MRK) Pneumococcal Vaccine Meets Late-Stage Study Goals
by Zacks Equity Research
Merck's (MRK) investigational 15-valent pneumococcal conjugate vaccine meets primary immunogenicity objectives in two late-stage studies in adults.
Will Lilly (LLY) Witness Recovery in Sales in Q3 Earnings?
by Zacks Equity Research
Higher demand for its growth drugs is likely to have offset generic competition for several other drugs to boost Lilly's (LLY) third-quarter sales.
Aptinyx (APTX) Surges on Promising Stress Disorder Study Data
by Zacks Equity Research
Aptinyx (APTX) is developing a NMDA receptor-targeted candidate, NYX-783, as potential treatment for post-traumatic stress disorder.
Pfizer (PFE) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Higher sales of Pfizer's (PFE) key brands, Eliquis, Ibrance and Inlyta, in the Biopharma segment are likely to have made up for lower sales in the Upjohn group in the third quarter.
5 Big Pharma/Biotech Stocks Set to Trump Q3 Earnings Estimates
by Zacks Equity Research
Let us take a look at some drug/biotech stocks including Glaxo (GSK) and Merck (MRK) that are poised to beat on earnings for the third quarter.
Sanofi's mRNA Vaccine for Coronavirus to Enter Clinical Stage
by Zacks Equity Research
Sanofi (SNY) and Translate Bio select coronavirus vaccine candidate MRT5500 for clinical development, based on its promising pre-clinical data. A clinical study is anticipated by this year-end.
Merck's Keytruda Gets FDA Nod for Expanded Use in Lymphoma
by Zacks Equity Research
The FDA approves Merck's (MRK) Keytruda for the treatment of adult patients with relapsed or refractory cHL who progress after frontline therapy.
The Zacks Analyst Blog Highlights: JNJ, Eli Lilly, Merck, AbbVie and GSK
by Zacks Equity Research
The Zacks Analyst Blog Highlights: JNJ, Eli Lilly, Merck, AbbVie and GSK
Do J&J's Q3 Results Indicate a Sales Recovery for Big Pharma?
by Kinjel Shah
Investors typically look at J&J's (JNJ) results for signals regarding how the rest of the big drugmakers will fare.
Sanofi's Dupixent Meets All Goals in Asthma Study for Children
by Zacks Equity Research
Sanofi's (SNY) blockbuster drug Dupixent meets primary as well as all key secondary goals in a late-stage study for treating moderate-to-severe asthma in children aged six-11 years.